Correction to: British Journal of Cancer (2008) 99, 1050–1055. doi:10.1038/sj.bjc.6604671
Upon publication of the above manuscript in Volume 99 of BJC, the authors noted a small error in the affiliations of L Paré, E del Rio, A Cortés and M Baiget. The full affiliations (addition in bold) is now shown below.
L Paré1, E Marcuello2, A Altés3, E del Río1,4, L Sedano4, J Salazar4, A Cortés1, A Barnadas2 and M Baiget1,4
1Department of Genetics, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona 08025, Spain; 2Department of Clinical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona 08025, Spain; 3Department of Hematology, Fundació Althaia, Manresa, Spain; 4Center for Biomedical Research on Rare Diseases (CIBERER), Barcelona 08025, Spain
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Additional information
The online version of the original article can be found at 10.1038/sj.bjc.6604671
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Paré, L., Marcuello, E., Altés, A. et al. Erratum: Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer 100, 1368 (2009). https://doi.org/10.1038/sj.bjc.6605004
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6605004
